IP Receptor Agonist Heterocyclic Compounds

IP Receptor Agonist Heterocyclic Compounds

The present invention provides heterocyclic derivatives which activate the IP receptor. Activating the IP receptor signaling pathway is useful to treat many forms of PAH, pulmonary fibrosis and exert beneficial effects in fibrotic conditions of various organs in animal models and in patients. Pharma...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: MCKEOWN STEPHEN CARL, BUTLER REBECCA, CHARLTON STEVEN JOHN, LEBLANC CATHERINE
Format: Patent
Sprache:eng
Schlagworte:
CHEMISTRY
HETEROCYCLIC COMPOUNDS
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
ORGANIC CHEMISTRY
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
Online-Zugang:Volltext bestellen
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page
container_issue
container_start_page
container_title
container_volume
creator MCKEOWN STEPHEN CARL
BUTLER REBECCA
CHARLTON STEVEN JOHN
LEBLANC CATHERINE
description The present invention provides heterocyclic derivatives which activate the IP receptor. Activating the IP receptor signaling pathway is useful to treat many forms of PAH, pulmonary fibrosis and exert beneficial effects in fibrotic conditions of various organs in animal models and in patients. Pharmaceutical compositions comprising such derivatives are also encompassed.
format Patent
fullrecord <record><control><sourceid>epo_EVB</sourceid><recordid>TN_cdi_epo_espacenet_US2015376183A1</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>US2015376183A1</sourcerecordid><originalsourceid>FETCH-epo_espacenet_US2015376183A13</originalsourceid><addsrcrecordid>eNrjZNDyDFAISk1OLSjJL1JwTM_PyywuUfBILUktyk-uTM7JTFZwzs8tyC_NSynmYWBNS8wpTuWF0twMym6uIc4euqkF-fGpxQWJyal5qSXxocFGBoamxuZmhhbGjobGxKkCALccKdU</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>patent</recordtype></control><display><type>patent</type><title>IP Receptor Agonist Heterocyclic Compounds</title><source>esp@cenet</source><creator>MCKEOWN STEPHEN CARL ; BUTLER REBECCA ; CHARLTON STEVEN JOHN ; LEBLANC CATHERINE</creator><creatorcontrib>MCKEOWN STEPHEN CARL ; BUTLER REBECCA ; CHARLTON STEVEN JOHN ; LEBLANC CATHERINE</creatorcontrib><description>The present invention provides heterocyclic derivatives which activate the IP receptor. Activating the IP receptor signaling pathway is useful to treat many forms of PAH, pulmonary fibrosis and exert beneficial effects in fibrotic conditions of various organs in animal models and in patients. Pharmaceutical compositions comprising such derivatives are also encompassed.</description><language>eng</language><subject>CHEMISTRY ; HETEROCYCLIC COMPOUNDS ; HUMAN NECESSITIES ; HYGIENE ; MEDICAL OR VETERINARY SCIENCE ; METALLURGY ; ORGANIC CHEMISTRY ; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</subject><creationdate>2015</creationdate><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&amp;date=20151231&amp;DB=EPODOC&amp;CC=US&amp;NR=2015376183A1$$EHTML$$P50$$Gepo$$Hfree_for_read</linktohtml><link.rule.ids>230,308,780,885,25564,76547</link.rule.ids><linktorsrc>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&amp;date=20151231&amp;DB=EPODOC&amp;CC=US&amp;NR=2015376183A1$$EView_record_in_European_Patent_Office$$FView_record_in_$$GEuropean_Patent_Office$$Hfree_for_read</linktorsrc></links><search><creatorcontrib>MCKEOWN STEPHEN CARL</creatorcontrib><creatorcontrib>BUTLER REBECCA</creatorcontrib><creatorcontrib>CHARLTON STEVEN JOHN</creatorcontrib><creatorcontrib>LEBLANC CATHERINE</creatorcontrib><title>IP Receptor Agonist Heterocyclic Compounds</title><description>The present invention provides heterocyclic derivatives which activate the IP receptor. Activating the IP receptor signaling pathway is useful to treat many forms of PAH, pulmonary fibrosis and exert beneficial effects in fibrotic conditions of various organs in animal models and in patients. Pharmaceutical compositions comprising such derivatives are also encompassed.</description><subject>CHEMISTRY</subject><subject>HETEROCYCLIC COMPOUNDS</subject><subject>HUMAN NECESSITIES</subject><subject>HYGIENE</subject><subject>MEDICAL OR VETERINARY SCIENCE</subject><subject>METALLURGY</subject><subject>ORGANIC CHEMISTRY</subject><subject>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</subject><fulltext>true</fulltext><rsrctype>patent</rsrctype><creationdate>2015</creationdate><recordtype>patent</recordtype><sourceid>EVB</sourceid><recordid>eNrjZNDyDFAISk1OLSjJL1JwTM_PyywuUfBILUktyk-uTM7JTFZwzs8tyC_NSynmYWBNS8wpTuWF0twMym6uIc4euqkF-fGpxQWJyal5qSXxocFGBoamxuZmhhbGjobGxKkCALccKdU</recordid><startdate>20151231</startdate><enddate>20151231</enddate><creator>MCKEOWN STEPHEN CARL</creator><creator>BUTLER REBECCA</creator><creator>CHARLTON STEVEN JOHN</creator><creator>LEBLANC CATHERINE</creator><scope>EVB</scope></search><sort><creationdate>20151231</creationdate><title>IP Receptor Agonist Heterocyclic Compounds</title><author>MCKEOWN STEPHEN CARL ; BUTLER REBECCA ; CHARLTON STEVEN JOHN ; LEBLANC CATHERINE</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-epo_espacenet_US2015376183A13</frbrgroupid><rsrctype>patents</rsrctype><prefilter>patents</prefilter><language>eng</language><creationdate>2015</creationdate><topic>CHEMISTRY</topic><topic>HETEROCYCLIC COMPOUNDS</topic><topic>HUMAN NECESSITIES</topic><topic>HYGIENE</topic><topic>MEDICAL OR VETERINARY SCIENCE</topic><topic>METALLURGY</topic><topic>ORGANIC CHEMISTRY</topic><topic>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</topic><toplevel>online_resources</toplevel><creatorcontrib>MCKEOWN STEPHEN CARL</creatorcontrib><creatorcontrib>BUTLER REBECCA</creatorcontrib><creatorcontrib>CHARLTON STEVEN JOHN</creatorcontrib><creatorcontrib>LEBLANC CATHERINE</creatorcontrib><collection>esp@cenet</collection></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>MCKEOWN STEPHEN CARL</au><au>BUTLER REBECCA</au><au>CHARLTON STEVEN JOHN</au><au>LEBLANC CATHERINE</au><format>patent</format><genre>patent</genre><ristype>GEN</ristype><title>IP Receptor Agonist Heterocyclic Compounds</title><date>2015-12-31</date><risdate>2015</risdate><abstract>The present invention provides heterocyclic derivatives which activate the IP receptor. Activating the IP receptor signaling pathway is useful to treat many forms of PAH, pulmonary fibrosis and exert beneficial effects in fibrotic conditions of various organs in animal models and in patients. Pharmaceutical compositions comprising such derivatives are also encompassed.</abstract><oa>free_for_read</oa></addata></record>
fulltext fulltext_linktorsrc
identifier
ispartof
issn
language eng
recordid cdi_epo_espacenet_US2015376183A1
source esp@cenet
subjects CHEMISTRY
HETEROCYCLIC COMPOUNDS
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
ORGANIC CHEMISTRY
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
title IP Receptor Agonist Heterocyclic Compounds
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-29T16%3A29%3A23IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-epo_EVB&rft_val_fmt=info:ofi/fmt:kev:mtx:patent&rft.genre=patent&rft.au=MCKEOWN%20STEPHEN%20CARL&rft.date=2015-12-31&rft_id=info:doi/&rft_dat=%3Cepo_EVB%3EUS2015376183A1%3C/epo_EVB%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true